Amrutanjan Health Care Limited (AHCL) reported a net profit of ₹4.37 crore for the quarter ended June 30, 2026 (Q1FY27), a decline of 47.7% from ₹8.31 crore in the corresponding period of FY26. While revenue from operations grew 9.5% year-on-year to ₹102.97 crore, profitability was significantly impacted by rising operational costs and a one-time exceptional expense related to a lease rent settlement.

The Board of Directors approved the unaudited financial results on August 11, 2026, following a review by the Audit Committee and a limited review report issued by statutory auditors B S R & Co. LLP. The company also announced its 89th Annual General Meeting (AGM) scheduled for September 23, 2026, via video conference. The record date for determining shareholder eligibility for voting and final dividend payment has been fixed as September 11, 2026.

Financial Performance

Revenue from operations increased to ₹10,296.88 lakh in Q1FY27 from ₹9,404.57 lakh in Q1FY26. However, total expenses rose sharply to ₹10,678.36 lakh from ₹9,847.31 lakh in the prior year. The profit before tax stood at ₹6.07 crore, down from ₹11.29 crore in Q1FY26, primarily due to the exceptional item and higher finance costs.

The net profit after tax for the quarter was ₹4.37 crore, compared to ₹8.31 crore in Q1FY26. Basic earnings per share fell to ₹1.51 from ₹2.87 in the previous year’s same quarter.

Exceptional Items and Segment Performance

A key drag on profitability was an exceptional item of ₹20.28 lakh, representing the additional cost settled with the Tamil Nadu HR & CE Department regarding retrospective lease rent revisions. This follows a legal dispute where the High Court of Judicature, Madras, upheld the fair rent determination, leading to a final settlement in August 2026. The company had previously created a provision of ₹760.50 lakh in the prior year; the additional provision reflects the final demand notice received in July 2026.

Segment-wise, OTC Products remained the largest revenue contributor at ₹57.26 crore, up slightly from ₹56.97 crore in Q1FY26. However, management commentary noted that the Pain Management category, which contributes 65% of company revenue, saw volume degrowth of 3.4% per IQVIA data, attributed to retailer demand erosion post-GST implementation and a high base effect.

Women’s Hygiene & Personal Care revenue grew strongly to ₹36.36 crore from ₹28.61 crore, a 27.1% increase. The Comfy brand specifically saw gross sales growth of 21%, driven by the XL variant (up 43%) and value packs (up 24%). Despite this top-line growth, the segment recorded a loss of ₹2.88 crore, compared to a profit of ₹1.49 lakh in the prior year, largely due to higher advertisement spend (₹2.14 crore vs ₹0.48 crore last year) and increased raw material costs.

Beverages revenue rose to ₹8.64 crore from ₹7.78 crore, though it incurred a loss of ₹12.60 lakh. The Electro+ brand saw significant traction, with Tetra pack sales growing 4x versus the prior year.

Operational Updates and New Launches

AHCL commissioned its new Greenfield Sanitary Napkin Manufacturing Facility in Telangana, a ₹150 crore investment spread across 10 acres. The facility features two fully automated high-speed production lines from Japan and marks the company’s fifth manufacturing plant.

Sales infrastructure expanded during the quarter, with stockist networks increasing by 7%, total outlet coverage by 17%, and effective outlet coverage by 8%. Productive calls rose by 9%, while total lines sold increased by 20%.

New launches contributed 4% to total AHCL sales in Q1FY27. Key additions include:

• Razors: Smoothe Men’s Razors and Comfy Women’s Razors generated ₹3 crore in revenue, reaching 70,000 outlets. Management projects annual revenues of ₹15 crore for these brands.
• Wound Care: The Plastery line generated ₹1.12 crore in revenue, with annual targets set at ₹10 crore.

What the Numbers Show

The divergence between top-line growth and bottom-line contraction highlights margin pressure across key segments. While OTC Products maintained healthy segment results of ₹9.87 crore, the losses in Women’s Hygiene & Personal Care and Beverages segments widened, offsetting gains. The recognition of the ₹20.28 lakh exceptional lease rent cost underscores the financial impact of prolonged regulatory disputes. Additionally, the aggressive investment in the Comfy brand—evidenced by a 338% increase in ad spend for the segment—suggests a strategic shift towards capturing market share in women's hygiene, albeit at the cost of near-term profitability in that division.

Amrutanjan Health Care Limited has fixed September 11, 2026, as the record date for the payment of its final dividend for the financial year 2025-26. This announcement determines which shareholders are eligible to receive the payout, establishing a clear cutoff for ownership verification. The declaration ensures that investors holding shares on or before this date will receive the declared dividend amount, subject to standard corporate action processing timelines.

The company notified the National Stock Exchange of India Limited and BSE Limited of this decision pursuant to Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. The filing confirms that eligibility is based on the register of members maintained by the company and the beneficial ownership details provided by National Securities Depository Limited (NSDL) and Central Depository Services (India) Limited (CDSL).

Key Dates and Details

Shareholders are advised to ensure their holdings are reflected in their demat accounts prior to the record date to secure entitlement. Any transfers or transactions occurring after the close of business on September 11, 2026, will not qualify for this specific dividend payment cycle.

What the Numbers Show

While the specific dividend per share amount was not disclosed in this particular regulatory filing, the establishment of a definitive record date signals the completion of the board’s approval process for the FY25-26 final distribution. For investors, the critical factor is maintaining continuous ownership through September 11, 2026, as any sale of shares after this date does not affect eligibility, whereas purchases made after this date will not carry the dividend right.